|
1
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ichinose Y, Yoshimori K, Sakai H, Nakai Y,
Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination
chemotherapy in patients with advanced non-small cell lung cancer:
A multi-institutional phase II trial. Clin Cancer Res.
10:7860–7864. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okamoto I, Yoshioka H, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naïve patients with advanced
non-small-cell lung cancer: Results of a west Japan oncology group
study. J Clin Oncol. 28:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yoshioka H, Okamoto I, Morita S, Ando M,
Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, et al:
Efficacy and safety analysis according to histology for S-1 in
combination with carboplatin as first-line chemotherapy in patients
with advanced non-small-cell lung cancer: Updated results of the
West Japan Oncology Group LETS study. Ann Oncol. 24:1326–1331.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maring JG, Groen HJ, Wachters FM, Uges DR
and de Vries EG: Genetic factors influencing pyrimidine-antagonist
chemotherapy. Pharmacogenomics J. 5:226–243. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takeda M, Okamoto I, Hirabayashi N, Kitano
M and Nakagawa K: Thymidylate synthase and dihydropyrimidine
dehydrogenase expression levels are associated with response to S-1
plus carboplatin in advanced non-small cell lung cancer. Lung
Cancer. 73:103–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaira K, Ohde Y, Nakagawa K, Okumura T,
Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M and Yamamoto
N: Thymidylate synthase expression is closely associated with
outcome in patients with pulmonary adenocarcinoma. Med Oncol.
29:1663–1672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishihama H, Chida M, Araki O, Karube Y,
Seki N, Tamura M, Umezu H, Honma K, Masawa N and Miyoshi S:
Comparison of 5-fluorouracil-related gene expression levels between
adenocarcinomas and squamous cell carcinomas of the lung. Jpn J
Clin Oncol. 39:33–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harada K, Kawashima Y, Yoshida H and Sato
M: Thymidylate synthase expression in oral squamous cell carcinoma
predicts response to S-1. Oncol Rep. 15:1417–1423. 2006.PubMed/NCBI
|
|
10
|
Koga M, Anegawa E, Yoh J, Tsuyama H,
Sakaino H, Iwamoto O, Koga C and Kusukawa J: Clinical relevance of
thymidylate synthase (TS) activity for S-1-based chemotherapy in
squamous cell carcinoma of the oral cavity. Br J Oral Maxillofac
Surg. 48:88–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria is solid tumours:
Revised RECIST guideline (Version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vilmar A, Garcia-Foncillas J, Huarriz M,
Santoni-Rugiu E and Sorensen JB: RT-PCR versus immunohistochemistry
for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1
in NSCLC. Lung Cancer. 75:306–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herpel E, Schnabel PA, Steins M, Dienemann
H, Herth FJ, Thomas M, Schirmacher P and Warth A: Assessment of
thymidylate synthase expression in biopsy specimens and
corresponding resection specimens of non-small-cell lung cancer.
Histopathology. 61:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicolson MC, Fennell DA, Ferry D, O'Byrne
K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, et
al: Thymidylate synthase expression and outcome of patients
receiving pemetrexed for advanced nonsquamous non-small-cell lung
cancer in a prospective blinded assessment phase II clinical trial.
J Thorac Oncol. 8:930–939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang T, Chuan Pan C, Rui Yu J, Long Y,
Hong Cai X, De Yin X, Qiong Hao L and Li Luo L: Association between
TYMS expression and efficacy of pemetrexed-based chemotherapy in
advanced non-small cell lung cancer: A meta-analysis. PLoS One.
8:e742842013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shimizu T, Nakanishi Y, Nakagawa Y,
Tsujino I, Takahashi N, Nemoto N and Hashimoto S: Association
between expression of thymidylate synthase, dihydrofolate
reductase, and glycinamide ribonucleotide formyltransferase and
efficacy of pemetrexed in advanced non-small cell lung cancer.
Anticancer Res. 32:4589–4596. 2012.PubMed/NCBI
|
|
17
|
Wynes MW, Konopa K, Singh S,
Reyna-Asuncion B, Ranger-Moore J, Sternau A, Christoph DC,
Dziadziuszko R, Jassem J and Hirsch FR: Thymidylate synthase
protein expression by IHC and gene copy number by SISH correlate
and show great variability in non-small cell lung cancer. J Thorac
Oncol. 7:982–992. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kasai D, Ozasa H, Oguri T, Miyazaki M,
Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K and Niimi A:
Thymidylate synthase gene copy number as a predictive marker for
response to pemetrexed treatment of lung adenocarcinoma. Anticancer
Res. 33:1935–1940. 2013.PubMed/NCBI
|
|
19
|
Lee SH, Noh KB, Lee JS, Lee EJ, Min KH,
Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, et al: Thymidylate synthase
and ERCC1 as predictive markers in patients with pulmonary
adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer.
81:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buqué A, Aresti U, Calvo B, Muhialdin ShJ,
Muñoz A, Carrera S, Azkona E, Rubio I and López-Vivanco G:
Thymidylate synthase expression determines pemetrexed targets and
resistance development in tumour cells. PLoS One. 8:e633382013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fukushima M, Morita M, Ikeda K and
Nagayama S: Population study of expression of thymidylate synthase
and dihydropyrimidine dehydrogenase in patients with solid tumors.
Int J Mol Med. 12:839–844. 2003.PubMed/NCBI
|
|
22
|
Ichikawa W, Takahashi T, Suto K, Shirota
Y, Nihei Z, Shimizu M, Sasaki Y and Hirayama R: Simple combinations
of 5-FU pathway genes predict the outcome of metastatic gastric
cancer patients treated by S-1. Int J Cancer. 119:1927–1933. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ichikawa W, Takahashi T, Suto K, Yamashita
T, Nihei Z, Shirota Y, Shimizu M, Sasaki Y and Hirayama R:
Thymidylate synthase predictive power is overcome by irinotecan
combination therapy with S-1 for gastric cancer. Br J Cancer.
91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shintani Y, Inoue M, Funakoshi Y,
Matsumura A, Ohta M, Maeda H and Okumura M: Low dihydropyrimidine
dehydrogenase crrelates with prolonged survival in patients with
lung adenocarcinoma treated with 5-fluorouracil. Anticancer Res.
31:4665–4671. 2011.PubMed/NCBI
|
|
25
|
Nakano J, Huang C, Liu D, Masuya D,
Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M:
Evaluations of biomarkers associated with 5-FU sensitivity for
non-small-cell lung cancer patients postoperatively treated with
UFT. Br J Cancer. 95:607–615. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto N, Yamanaka T, Ichinose Y, Kubota
K, Sakai H, Gemma A, Saijo N, Fukuoka M and Niitani H: Pooled
analysis of S-1 trials in non-small cell lung cancer according to
histological type. Anticancer Res. 30:2985–2990. 2010.PubMed/NCBI
|
